Skip to main content
Premium Trial:

Request an Annual Quote

Denis O’Shaughnessy

Premium
Acuity Pharmaceuticals has appointed Denis O’Shaughnessy as its senior vice president of clinical development.
 
O’Shaughnessy was formerly senior vice president of clinical development and co-founder of Eyetech Pharmaceuticals, where he oversaw development of the wet age-related macular degeneration drug Macugen. Before this, he was director of clinical operations and department head at Hoffman-La Roche. He has also held positions at Cyanamid, Sandoz, Xoma, and Celltech.
 
“As we prepare to move into later stage trials with our lead compound bevasiranib, this experience should be of tremendous value in ensuring that our clinical program is optimally designed and executed,” Acuity President and CEO Dale Pfost said in a statement.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.